Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | PDE6A | P16499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441090 | 0.91 | KCNH2 (0.38) | XDHGRIN1GRIN2B | |
| SCHEMBL5433740 | 0.89 | GRIN1 (0.41) | XDHGRIN1GRIN2B | |
| SCHEMBL5433300 | 0.88 | CYP3A4 (0.38) | CYP3A4CYP2C19XDHGRIN1GRIN2B | |
| SCHEMBL5438859 | 0.87 | CCKAR (0.40) | XDH | |
| SCHEMBL5439377 | 0.87 | AGTR1 (0.40) | GRIN1GRIN2B | |
| SCHEMBL5439005 | 0.87 | XDH (0.37) | XDH | |
| SCHEMBL5437190 | 0.86 | XDH (0.38) | CYP3A4CYP2C19XDH | |
| SCHEMBL5445861 | 0.86 | XDH (0.38) | XDHGRIN1GRIN2BSCN9A | |
| SCHEMBL5434679 | 0.85 | SCN9A (0.41) | CYP3A4CYP2C19XDHSCN9A | |
| SCHEMBL5439364 | 0.84 | XDH (0.35) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) | 2007-07-19 | — | — | US | claimed |
| JP-2007516158-A | — | — | 2007-06-21 | — | — | JP | claimed |
| EP-1613634-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-01-11 | — | — | EP | claimed |
| WO-2004087714-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-10-14 | — | — | WO | claimed |
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) | 2007-07-19 | — | — | US | disclosed |
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) | 2007-07-19 | — | — | US | disclosed |
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) | 2007-07-19 | — | — | US | disclosed |
| EP-1613634-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087714-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | IDO1, NAT1, AANAT | CYP3A4 116/4885CYP2C19 984/4885XDH 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.